基于母体血清代谢组学特征的先天性缺陷筛查试验方案
该多中心观察性回顾性研究基于母体血清代谢组学构建集成机器学习模型,在654名意大利孕妇中训练,在新西兰1935名参与者中验证;验证队列准确率99.4%±0.6%,特异性99.9%±0.1%,敏感性78%±6%。
要点
- 母体血清代谢组学联合集成机器学习模型可用于产前筛查先天性缺陷。
- 验证队列中筛查试验准确率99.4%±0.6%,特异性99.9%±0.1%,敏感性78%±6%。
- 研究认为需进一步研究以识别畸形类型并在更大样本中验证。
核心结论
- 本研究为基于代谢组学的产前筛查试验检测先天性缺陷的存在提供了临床验证。
- 需进一步研究以识别畸形类型并在更大研究人群中确认这些发现。
研究设计与样本
- 多中心观察性回顾性研究,包含两个分支。
- 第一分支纳入654名意大利孕妇(334例胎儿畸形病例和320例发育正常胎儿对照),用于训练基于血清代谢组学图谱的集成机器学习分类模型。
- 第二分支对来自新西兰妊娠终点筛查研究的1935名参与者的血清样本进行盲法分析,作为验证队列。
- 采用气相色谱-质谱联用进行非靶向代谢组学分析。
- 构建并优化9种个体机器学习分类模型,包括偏最小二乘判别分析、线性判别分析、朴素贝叶斯、决策树、随机森林、k近邻、人工神经网络、支持向量机和逻辑回归;根据个体模型的交叉验证准确率和分类置信度进行统计加权投票方案,开发集成模型。
主要发现
- 与对照相比,怀有畸形胎儿的孕妇血清中棕榈酸、肉豆蔻酸、硬脂酸、N-α-乙酰赖氨酸、葡萄糖、L-乙酰肉碱、果糖、对甲酚和木糖水平较低,丝氨酸、丙氨酸、尿素、孕酮和缬氨酸水平较高(P<.05)。
- 在验证队列中,筛查试验准确率为99.4%±0.6%,特异性为99.9%±0.1%(1894名对照中1892名正确识别),敏感性为78%±6%(41例胎儿畸形中32例正确识别)。
关键数值与推荐
- 验证队列准确率99.4%±0.6%。
- 验证队列特异性99.9%±0.1%(1894名对照中1892名正确识别)。
- 验证队列敏感性78%±6%(41例胎儿畸形中32例正确识别)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以识别畸形类型。
- 需在更大研究人群中确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, noninvasive techniques are only able to identify chromosomal anomalies that accounted for <50% of all congenital defects; the other congenital defects are diagnosed via ultrasound evaluations in the later stages of pregnancy. Metabolomic analysis may provide an important improvement, potentially addressing the need for novel noninvasive and multicomprehensive early prenatal screening tools. A growing body of evidence outlines notable metabolic alterations in different biofluids derived from pregnant women carrying fetuses with malformations, suggesting that such an approach may allow the discovery of biomarkers common to most fetal malformations. In addition, metabolomic investigations are inexpensive, fast, and risk-free and often generate high performance screening tests that may allow early detection of a given pathology. OBJECTIVE: This study aimed to evaluate the diagnostic accuracy of an ensemble machine learning model based on maternal serum metabolomic signatures for detecting fetal malformations, including both chromosomal anomalies and structural defects. STUDY DESIGN: This was a multicenter observational retrospective study that included 2 different arms. In the first arm, a total of 654 Italian pregnant women (334 cases with fetuses with malformations and 320 controls with normal developing fetuses) were enrolled and used to train an ensemble machine learning classification model based on serum metabolomics profiles. In the second arm, serum samples obtained from 1935 participants of the New Zealand Screening for Pregnancy Endpoints study were blindly analyzed and used as a validation cohort. Untargeted metabolomics analysis was performed via gas chromatography-mass spectrometry. Of note, 9 individual machine learning classification models were built and optimized via cross-validation (partial least squares-discriminant analysis, linear discriminant analysis, naïve Bayes, decision tree, random forest, k-nearest neighbor, artificial neural network, support vector machine, and logistic regression). An ensemble of the models was developed according to a voting scheme statistically weighted by the cross-validation accuracy and classification confidence of the individual models. This ensemble machine learning system was used to screen the validation cohort. RESULTS: Significant metabolic differences were detected in women carrying fetuses with malformations, who exhibited lower amounts of palmitic, myristic, and stearic acids; N-α-acetyllysine; glucose; L-acetylcarnitine; fructose; para-cresol; and xylose and higher levels of serine, alanine, urea, progesterone, and valine (P<.05), compared with controls. When applied to the validation cohort, the screening test showed a 99.4%±0.6% accuracy (specificity of 99.9%±0.1% [1892 of 1894 controls correctly identified] with a sensitivity of 78%±6% [32 of 41 fetal malformations correctly identified]). CONCLUSION: This study provided clinical validation of a metabolomics-based prenatal screening test to detect the presence of congenital defects. Further investigations are needed to enable the identification of the type of malformation and to confirm these findings on even larger study populations.
引用
- Troisi J, Lombardi M, Scala G, et al. A screening test proposal for congenital defects based on maternal serum metabolomics profile. Am J Obstet Gynecol. 2022. PMID: 36075482. doi:10.1016/j.ajog.2022.08.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。